financetom
Business
financetom
/
Business
/
Amgen Reaches Deal to Resolve Patent Disputes With Sandoz
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amgen Reaches Deal to Resolve Patent Disputes With Sandoz
Apr 30, 2024 3:07 AM

05:58 AM EDT, 04/30/2024 (MT Newswires) -- Amgen ( AMGN ) and Sandoz reached an agreement to resolve their patent disputes related to Sandoz's denosumab biosimilars, according to a Tuesday statement from Sandoz.

In May 2023 patent infringement proceedings, Amgen ( AMGN ) claimed that Sandoz infringed up to 21 patents covering its reference medicines Prolia and Xgeva.

Sandoz said the settlement deal will allow it to enter the US market with a biosimilar version of Prolia and Xgeva on May 31, 2025, or earlier under certain circumstances.

No other settlement terms were disclosed.

Price: 276.26, Change: -0.12, Percent Change: -0.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved